33768803|t|Autologous hematopoietic transplantation following COVID-19 infection.
33768803|a|Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID-19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.
33768803	51	69	COVID-19 infection	Disease	MESH:D000086382
33768803	174	182	patients	Species	9606
33768803	204	220	multiple myeloma	Disease	MESH:D009101
33768803	267	285	COVID-19 infection	Disease	MESH:D000086382

